LISATA THERAPEUTICS, INC.(LSTA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Limited institutional coverage
Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 35 institutional filers currently hold this stock.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
LSTA Stock Analysis & AI Quality Score
AI stock analysis and institutional research for LISATA THERAPEUTICS, INC. (LSTA), a Healthcare sector company. LSTA is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 35 institutional filers currently hold this stock. Based on the latest XBRL financial filings (Q1 2026), LISATA THERAPEUTICS, INC. reports net income of $-4.5M, free cash flow of $-3.1M. Top institutional holders of LSTA by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, RENAISSANCE TECHNOLOGIES, DELTEC ASSET MANAGEMENT, based on the most recent SEC filings. LSTA trades on the Nasdaq exchange and files with the SEC under CIK 320017. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate LSTA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for LISATA THERAPEUTICS, INC. directly from SEC EDGAR.
Revenue
Q1 2026
$0.00
Net Income
Q1 2026
$-4.5M
Free Cash Flow
Q1 2026
$-3.1M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
Net Income
+20.4% YoYOperating Income
+29.2% YoYEPS (Diluted)
+26.0% YoYTotal Assets
-67.6% YoYOp. Cash Flow
+20.4% YoY| Metric | FY 2025 | FY 2023 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
| Revenue | $170.0K | $0.00 | — | — | — | — |
| Net Income | $-16.6M +20.4% | $-20.8M +24.1% | $-27.5M -237.0% | $-8.2M +57.9% | $-19.4M -19.8% | $-16.2M |
| Operating Income | $-18.2M +29.2% | $-25.7M +11.5% | $-29.1M -51.7% | $-19.1M +4.7% | $-20.1M -18.3% | $-17.0M |
| EPS (Diluted) | $-1.91 +26.0% | $-2.58 -419.4% | $-0.50 -4109.3% | $-0.01 | — | — |
| Total Assets | $17.7M -67.6% | $54.7M -43.6% | $97.0M +169.5% | $36.0M +32.6% | $27.2M -39.1% | $44.6M |
| Operating Cash Flow | $-15.9M +20.4% | $-20.0M +9.9% | $-22.2M -152.1% | $-8.8M +53.3% | $-18.9M +5.5% | $-20.0M |
AI Insight: LSTA Ratio Trends
Return metrics have deteriorated sharply through Q3 2025 before a Q4 2025 distortion, with ROE plunging to -164.3% in Q1 2026 — signaling accelerating cash burn for this pre-revenue biotech.
• ROE worsened steadily from -50.2% in Q1 2024 to -97.8% in Q3 2025, reflecting consistent and deepening net losses.
• ROA deteriorated from -44.8% in Q1 2024 to -78.1% in Q3 2025, indicating assets are increasingly inefficient relative to losses.
• ROIC contracted from -61.4% in Q1 2024 to -92.6% in Q2 2025, the last available reading, pointing to worsening capital deployment.
⚠ ROE swung to -32.6% in Q4 2025 before crashing to -164.3% in Q1 2026 — one-off items or equity changes warrant close scrutiny.
⚠ OpMargin, NPM, and D/E remain entirely unreported; absence of revenue-side and leverage data limits fundamental assessment.
Get alerted when LSTA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for LISATA THERAPEUTICS, INC. including:
Top Institutional Holders of LSTA
VANGUARD CAPITAL MANAGEMENT LLC
$1.4M271,815 shRENAISSANCE TECHNOLOGIES LLC
$659.9K131,715 shDELTEC ASSET MANAGEMENT LLC
$450.9K90,000 shRangeley Capital, LLC
$375.8K75,000 shGEODE CAPITAL MANAGEMENT, LLC
$355.2K70,887 shCSS LLC/IL
$310.1K61,898 shBlackRock, Inc.
$274.8K54,857 shPenderFund Capital Management Ltd.
$238.0K47,500 shVANGUARD FIDUCIARY TRUST CO
$174.9K34,917 shGTS SECURITIES LLC
$157.3K31,396 sh
| Fund | Value | Shares |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $1.4M | 271,815 |
| RENAISSANCE TECHNOLOGIES LLC | $659.9K | 131,715 |
| DELTEC ASSET MANAGEMENT LLC | $450.9K | 90,000 |
| Rangeley Capital, LLC | $375.8K | 75,000 |
| GEODE CAPITAL MANAGEMENT, LLC | $355.2K | 70,887 |
| CSS LLC/IL | $310.1K | 61,898 |
| BlackRock, Inc. | $274.8K | 54,857 |
| PenderFund Capital Management Ltd. | $238.0K | 47,500 |
| VANGUARD FIDUCIARY TRUST CO | $174.9K | 34,917 |
| GTS SECURITIES LLC | $157.3K | 31,396 |
More Healthcare Companies
View all Healthcare →Put LSTA on your watchlist
Track score changes the day LISATA THERAPEUTICS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is LSTA a good stock to buy?
13F Pro's AI-powered analysis of LISATA THERAPEUTICS, INC. (LSTA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for LSTA are available on the LSTA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own LSTA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling LSTA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of LISATA THERAPEUTICS, INC.'s investment landscape.